Viewing Study NCT00243568

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:41 PM
Ignite Modification Date: 2026-05-30 @ 10:23 PM
Study NCT ID: NCT00243568
Status: WITHDRAWN
Last Update Posted: 2019-09-12
First Post: 2005-10-20
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285
Sponsor: Merck Sharp & Dohme LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None HIV Infections View
None Acquired Immunodeficiency Syndrome View
Keywords:

Keywords

Keyword Brief Keyword Text View
None HIV Infections View
None vicriviroc View
None Acquired Immunodeficiency Syndrome View
None CCR5/CXCR4 mixed tropism View
None R5/X4 mixed tropism View
None CCR5 inhibitor View
None treatment-experienced View